Pharmaceutical Technology

MARCH 9, 2023

Innovation S-curve for the pharmaceutical industry Transgenic murine models is a key innovation area in pharmaceutical s Transgenic murine models refer to mice that have been genetically altered for the purposes of understanding the in vivo functions of genes. Regeneron Pharmaceuticals is the leading patent filer in transgenic murine models.

In-Vivo 130

In-Vivo Antibody Genetics Gene 130

pharmaphorum

FEBRUARY 13, 2022

Quris’ BioAI safety prediction platform – which is based on human tissue samples on chips, nanosensors and machine learning – will be compared to traditional in vitro and in vivo laboratory techniques for spotting toxicity. The post Merck will assess Quris’ AI ‘patient-on-a-chip’ drug safety appeared first on.

Drugs 98

Drugs In-Vivo In-Vitro Pharma Companies 98

Roots Analysis

DECEMBER 8, 2021

Biopreservation is the exclusive biological approach designated for the preservation of cells, tissues and organs ex-vivo for the purpose of storage, shipment and transportation. Biopreservation media is one of the most crucial entity in conferring effectiveness. F) to 8°C (46.4°F).

Packaging 52

Packaging Packaging In-Vivo Biobanking 52

Drug Discovery World

JULY 22, 2022

In vivo models, particularly HIS models, allow preliminary investigation of cell-based therapeutic strategies—often in combination with other therapeutic modalities—to overcome the limitations and challenges of T cell-based immuno-oncology treatments and identify effective options for clinical investigation. Jespersen et al.

In-Vivo 52

In-Vivo Engineer In-Vitro Antibody 52

FDA Law Blog

OCTOBER 10, 2023

Having a clear understanding of FDA’s data expectations for 510(k) applications related to implants is crucial for successful marketing clearance. Implant devices are used in a range of settings such as dental and orthopedic procedures. The intended duration of implantation is another crucial factor in performance testing.

In-Vivo 45

In-Vivo Manufacturing Engineer Genotoxicity 45

pharmaphorum

JANUARY 25, 2022

As the area of bringing a digital therapeutic to market means passing the same level of regulatory scrutiny as a traditional, pharmaceutical therapy, this means “prescription digital therapeutics must undergo extensive clinical trials to demonstrate their safety and effectiveness before they ever reach patients,” said McCann.

Medicine 110

Medicine In-Vivo In-Vitro Development 110

Drug Discovery World

MARCH 12, 2024

Secondly, the programme has supported a focus on scientific excellence, which enabled us to release our study on the manufacturing of Velban from our engineered yeast cell factories as a proof-of- concept documenting Biomia’s biosynthesis platform. RA: Biomia is developing drug candidates for pain, addiction and mental health conditions.

Medicine 59

Medicine Production Drugs In-Vivo 59

Drug Discovery World

FEBRUARY 6, 2023

MT: Can you provide me with an overview of what Infinimmune does currently and the potential it sees in the antibody-based therapeutics market? We isolate antibodies from single human B cells using single cell genomics and assess, engineer, and advance these antibodies with other technologies.

Antibody 52

Antibody Immune Response Genome Genomics 52

Drug Discovery World

NOVEMBER 16, 2022

Therefore, while researchers can understand just how a drug molecule impacts a cell, they can’t be sure that it will perform the same when used in-vivo. . One of these benefits is how cells grown in this type of culture are able to interact with their surroundings, similar to how they would perform in-vivo. 2D vs 3D .

Drugs 97

Drugs In-Vivo In-Vitro Scientist 97

The Pharma Data

JANUARY 11, 2021

Our antibody clones in their original IgG format have shown potent neutralization activity in in vitro assays and, in the case of our lead clone, in an in vivo animal model. Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies.

Antibody 52

Antibody Licensing Licensing Development 52

FDA Law Blog

JANUARY 2, 2022

The Draft Guidance describes a nine-step framework for evaluating the credibility of CM&S information submitted in pre-market applications. Computational modeling and simulation (CM&S) can sometimes be useful to demonstrate the safety and effectiveness of medical devices or incorporated into devices. Draft Guidance at 4.

In-Vivo 52

In-Vivo Development Engineer Clinical Trials 52

Drug Discovery World

JULY 5, 2023

Global Cancer Segment Market Manager at Agilent Technologies, recently sat down with DDW Editor Reece Armstrong to tell us about the developments in the ‘golden age’ of cancer research. Mark Garner, PhD., RA: Please can you tell us a bit more about your role at Agilent? MG: I am responsible for Agilent’s cancer segment.

Research 98

Research Protein Scientist Immune Response 98

The Pharma Data

NOVEMBER 15, 2020

Pre-clinical studies of MINIject highlighting the anti-fibrotic properties of its STAR ® material were recently published in BMC Biomedical Engineering. . Promising MINIject data at two years from the STAR-I trial were recently published in the British Journal of Ophthalmology. medications at baseline).

Trials 52

Trials In-Vivo Engineer Clinical Trials 52

FDA Law Blog

JANUARY 2, 2022

The Draft Guidance describes a nine-step framework for evaluating the credibility of CM&S information submitted in pre-market applications. Computational modeling and simulation (CM&S) can sometimes be useful to demonstrate the safety and effectiveness of medical devices or incorporated into devices. Draft Guidance at 4.

In-Vivo 40

In-Vivo Regulation Development Engineer 40

Drug Discovery World

NOVEMBER 9, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Croasdale-Wood will then participate in a keynote chat, interviewed by Miho.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Drug Discovery World

APRIL 3, 2023

DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did you imagine you would one day be operating on such a global scale?    I quickly recognised the commercial value of aptamers as being able to address the gap in the market where antibodies fail to perform, and together we established the business to begin aptamer development.

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting.

Antibody 64

Antibody Engineer Protein Scientist 64

Drug Discovery World

SEPTEMBER 6, 2022

This area of medicine, which turns our own bodies into agents of combat to fight disease, has quickly become one of the most promising fields in treating deadly diseases such as cancer, central nervous system disorders and even musculoskeletal conditions. . Last year saw the sector surge, with levels of investment hitting an all-time high at $22.7

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

Pharmaceutical Technology

JULY 20, 2022

The alliance plans to leverage the single-cell adeno-associated virus (AAV) engineering (scAAVengr) platform technology of Avista to develop intravitreal AAV capsids for a Roche-defined profile. Roche will use these new capsids to carry out preclinical, clinical and marketing activities for gene therapy programmes.

Gene Therapy 147

Gene Therapy Gene Development In-Vivo 147

The Pharma Data

JANUARY 4, 2021

Kiromic chPD1 has shown in preclinical data to show a cytotoxic response in 9 different in vivo models with 100% long-term PFS with the induction of host memory responses. chPD1 will be used in the Company’s proprietary chimeric antigen receptor therapy (CAR-T) platform using gamma-delta T-cells (GD-T). About Kiromic.

In-Vivo 40

In-Vivo Development Big Data Immune Response 40

Drug Discovery World

NOVEMBER 13, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Ali Madani, PhD, Founder and CEO, Profluent Bio, on: ‘Protein engineering with large language models’.

Protein 59

Protein Antibody Engineer Scientist 59

The Pharma Data

DECEMBER 10, 2020

ImmunityBio has engineered the vector to overcome this problem and has shown that its second-generation adenovirus vector can safely and effectively deliver its cargo even in patients with pre-existing adenovirus immunity. This blocking of viral replication was observed in both the lung and nasal passages.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

Pharmaceutical Technology

FEBRUARY 15, 2023

Innovation S-curve for the pharmaceutical industry Gene splicing using nucleases is a key innovation area in the pharmaceutical industry Nucleases play a fundamental role in the field of recombinant DNA technology, or genetic engineering. However, not all innovations are equal and nor do they follow a constant upward trend.

Gene Splicing 130

Gene Splicing Gene Recombinant DNA Technology DNA 130

XTalks

DECEMBER 20, 2023

As we step into 2024, the life sciences continue to evolve at an unprecedented pace, driven by technological innovation, a deeper understanding of human biology and the application of new technologies in areas like drug development and health wearables. Regulatory bodies are also taking note of the applications of AI in drug development.

Life Science 119

Life Science Gene Editing Development Clinical Trials 119

Drug Discovery World

OCTOBER 17, 2022

By Dr Christof Gänzler, Product Marketing Biology at PerkinElmer Informatics. . In today’s quest to accelerate time to market for novel drugs, part of the success formula requires leveraging discovery data with more precision and speed, and earlier in the process. It takes more than speed to advance and maintain performance.

Marketing 52

Marketing Scientist Gene Expression Drugs 52

Drug Discovery World

JANUARY 23, 2023

Our team has been focused on engineering mRNA so that it’s only used to express cargo protein in certain cells regardless of where the molecule ends up in the body. JB : Strand was founded in 2018, and our programmable mRNA technology has broad applicability across a variety of diseases.

RNA 98

RNA Genome Genomics Engineer 98

Drug Discovery World

NOVEMBER 15, 2022

The brainchild of multidisciplinary experts in computer science, physics, engineering, and biology, the field of synthetic biology has not only rapidly progressed in the last few decades but it’s also becoming more accessible and cost-effective. If there’s a mismatch between two strands, the DNA will melt away at a lower temperature.

DNA 98

DNA Drugs Antibody Engineer 98

Roots Analysis

SEPTEMBER 18, 2023

Owing to the ability to preserve a wide variety of elements for such a long period of time, including cells, tissues, blood and DNA, cryopreservation has emerged as a key focus area for stakeholders in the biopharmaceutical industry. Therefore, in order to store and preserve such enormous amounts of blood, single-use assemblies are a necessity.

Engineer 52

Engineer Containment In-Vivo Production 52

Drug Discovery World

NOVEMBER 30, 2023

DDW’s Megan Thomas attended PEGS Europe 2023 in Lisbon, Portugal, from Tuesday 14 November to Thursday 16 November 2023. The company’s goal is to accelerate functional characterisation and shortenoptimisation time in antibody discovery and t-cell workflows. GSK has developed high-throughput mammalian and E.

Antibody 59

Antibody Protein Engineer In-Vivo 59

Drug Discovery World

FEBRUARY 15, 2023

Sophisticated and continually evolving preclinical IO models (in vivo and in vitro) are particularly helpful in defining translational therapeutic strategies and understanding the efficacy of combination immunotherapies and refractory cancers, and in the identification of novel prognostic biomarkers.

Research 52

Research In-Vitro In-Vivo Development 52

Roots Analysis

SEPTEMBER 13, 2023

The synergistic behavior achieved from the process circumvents the inherent limitation of the individual counterparts, such as short in vivo half-life, low solubility and immunogenicity. It consists of somatostatin-derived peptide and DOTA complexed with radioactive isotope 77 Lu.

Development 40

Development Antibody Protein Drug Delivery Systems 40

XTalks

AUGUST 19, 2022

Zynteglo is administered as a one-time treatment, with each dose consisting of a patient’s own bone marrow stem cells engineered to make functional beta-globin through insertion of working copies of the beta-globin gene. The cells are prepared outside of the body ( ex vivo ) and then infused into the patient.

Gene Therapy 95

Gene Therapy FDA Approval Gene Clinical Trials 95

Drug Discovery World

DECEMBER 13, 2023

Fortis Life Sciences offers custom antibody discovery and manufacturing services for antibodies and single-domain antibodies, supporting the drug discovery market. Fortis Life Sciences offers custom antibody discovery and manufacturing services for antibodies and single-domain antibodies, supporting the drug discovery market.

Life Science 59

Life Science Antibody Manufacturing In-Vivo 59

Drug Discovery World

FEBRUARY 26, 2024

These therapies, which utilise human cells to replace diseased or damaged cells or use engineered cells to act as therapies for a specific disease, have become more common in recent years, with approvals and clinical trials increasing. Challenges “There are some cell therapies on the market but the cost of those is maybe $500,000 a dose.

Manufacturing 52

Manufacturing In-Vivo Development Production 52

Drug Discovery World

FEBRUARY 1, 2024

From this enriched selection, promising candidates are identified only after each antibody is characterised both in vitro and in vivo. Time can mean more than money when you’re studying a deadly pathogen. When all is said and done, this process may take months or years to complete.

Antibody 64

Antibody Gene Protein Manufacturing 64

The Pharma Data

OCTOBER 15, 2020

marketing and diagnostics. He is currently a professor at the University of Copenhagen where his lab focuses on PNAs in regard to drug discovery, gene targeting, antisense principles, cellular and in vivo delivery and administration of biopharmaceuticals. BeyondSpring – BeyondSpring Inc. At Spark, he served as head of U.S.

In-Vivo 52

In-Vivo Business Development Manufacturing Development 52

The Pharma Data

OCTOBER 26, 2020

Following the unauthorized download of all abstracts on the SITC website, Transgene is communicating the content of the late-breaking poster abstract that will be presented at the SITC 35th Anniversary Annual Meeting (SITC 2020), to be held virtually November 9-14, 2020. Key findings of the trial: .

Vaccination 52

Vaccination Vaccine Trials Containment 52